Legislators Propose a Registry to Track Clinical Trials From Start to Finish

摘要

Data from company-sponsored clinical trials are often treated as business secrets, but that practice may soon change. In the wake of allegations that a few companies have suppressed negative results to promote their drugs, some members of Congress say they intend to make it easier for the public to track clinical studies. Democrats plan to introduce legislation in both the House and Senate this month to create a mandatory public registry. It would require that all clinical studies be described publicly at their inception and that results be added when a trial is complete.